These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22692980)

  • 1. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 2. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 6. One community. The B. Chevalier Lecture, held at the EORTC New Drugs Meeting, Lugano, Switzerland, 19-21 June 1997.
    Wittes RE; Yoder O
    Ann Oncol; 1998 Mar; 9(3):251-4. PubMed ID: 9602257
    [No Abstract]   [Full Text] [Related]  

  • 7. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

  • 8. [Off-label use in oncology. The Italian choice].
    Felicetti V; Gremigni U; Cifaldi L
    Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 11. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 13. Epigenetic drugs against cancer: an evolving landscape.
    Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
    Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating epigenetics into an anticancer drug pipeline for solid tumors.
    Roukos DH
    Expert Rev Med Devices; 2011 Jul; 8(4):409-13. PubMed ID: 21728725
    [No Abstract]   [Full Text] [Related]  

  • 15. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 16. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 17. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 20. Conflicting signals on US accelerated approvals.
    Fox JL
    Nat Biotechnol; 2005 Sep; 23(9):1027-8. PubMed ID: 16151377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.